Tysabri price to rise 21%
The price of Biogen Idec and Elan’s recently re-approved multiple sclerosis medication Tysabri will rise approximately 21%, according to Elan’s ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.